JP2023534300A5 - - Google Patents

Info

Publication number
JP2023534300A5
JP2023534300A5 JP2023503154A JP2023503154A JP2023534300A5 JP 2023534300 A5 JP2023534300 A5 JP 2023534300A5 JP 2023503154 A JP2023503154 A JP 2023503154A JP 2023503154 A JP2023503154 A JP 2023503154A JP 2023534300 A5 JP2023534300 A5 JP 2023534300A5
Authority
JP
Japan
Prior art keywords
composition
cancer
fusion peptide
anticancer therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534300A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/050770 external-priority patent/WO2022011434A1/en
Publication of JP2023534300A publication Critical patent/JP2023534300A/ja
Publication of JP2023534300A5 publication Critical patent/JP2023534300A5/ja
Pending legal-status Critical Current

Links

JP2023503154A 2020-07-17 2021-07-16 癌の処置のための組成物および方法 Pending JP2023534300A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902478A AU2020902478A0 (en) 2020-07-17 Compositions and methods for the treatment of cancer
AU2020902478 2020-07-17
PCT/AU2021/050770 WO2022011434A1 (en) 2020-07-17 2021-07-16 Compositions and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023534300A JP2023534300A (ja) 2023-08-08
JP2023534300A5 true JP2023534300A5 (https=) 2024-07-30

Family

ID=79555877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503154A Pending JP2023534300A (ja) 2020-07-17 2021-07-16 癌の処置のための組成物および方法

Country Status (6)

Country Link
US (1) US20240391964A1 (https=)
EP (1) EP4182334A4 (https=)
JP (1) JP2023534300A (https=)
AU (1) AU2021309132A1 (https=)
CA (1) CA3189545A1 (https=)
WO (1) WO2022011434A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178414A1 (ko) * 2024-02-22 2025-08-28 (주)에스엔이바이오 막관통 도메인을 포함하는 약물 전달체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659412B2 (en) * 1990-06-25 1995-05-18 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors
WO2007044321A2 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
CN101481422B (zh) * 2009-02-09 2011-05-18 孙妙囡 一种具有释药开关的抗肿瘤靶向融合蛋白及其应用
DK2445515T3 (en) * 2009-06-26 2016-07-04 Univ Leuven Kath antimicrobial agents
CN103755813B (zh) * 2014-01-07 2016-08-10 中国人民解放军第二军医大学 一种靶向性抗肿瘤融合蛋白及其编码基因与表达质粒
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
CN109439686B (zh) * 2018-11-23 2022-07-01 天津农学院 一种重组减毒沙门氏菌lh430及其制备方法和用途

Similar Documents

Publication Publication Date Title
Shi Clinical translation of nanomedicine and biomaterials for cancer immunotherapy: progress and perspectives
JP6787792B2 (ja) がんの処置のための併用治療
Roy et al. Advancements in cancer immunotherapies
Geller et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer
JP2016530323A5 (https=)
Kubicek et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies
Dima et al. Management of relapsed–refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice
AU2015267897A1 (en) Pharmaceutical solution having anti-tumor effect-enhancing and toxicity-reducing effect, and pharmaceutical composition comprising same
CN109475636A (zh) 药物-递送纳米颗粒和耐药癌症的治疗
Chami et al. Radiation and immune checkpoint inhibitors: combination therapy for treatment of hepatocellular carcinoma
Saito et al. Anatomical targeting of anticancer drugs to solid tumors using specific administration routes
Ghobrial et al. Phase Ib study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide plus low-dose dexamethasone, or with bortezomib plus dexamethasone in subjects with relapsed or refractory multiple myeloma
Cunningham et al. Recombinant endostatin as a potential radiosensitizer in the treatment of non-small cell lung cancer
Ros et al. A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world
Qin et al. CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
JP2022501332A5 (https=)
Melzig et al. Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy
JP2023534300A5 (https=)
Andrade et al. The nanotechnology-based approaches against kirsten rat sarcoma-mutated cancers
CA2824417C (en) Mycobacterium w for use in treating cancer
Wang et al. Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients
JP2016522826A5 (https=)
JP2024527180A5 (https=)
JP2025505652A5 (https=)
Cardoso et al. 5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab